Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus
Authors:
- Nobuaki OzakiNONobuaki Ozaki
- Yoshio NomuraYNYoshio Nomura
- Hiroshi SobajimaHSHiroshi Sobajima
- Kunikazu KondoKKKunikazu Kondo
- Yutaka OisoYOYutaka Oiso
- 30 June 2010
- journal article
- research article
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 21 (3) , 236-239
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- New Treatment Strategies for Patients with Hypertension and Insulin ResistanceThe American Journal of Medicine, 2006
- Comparison of the Effects of Ramipril Versus Telmisartan in Reducing Serum Levels of High-Sensitivity C-Reactive Protein and Oxidized Low-Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes MellitusThe American Journal of Cardiology, 2005
- Replacement of Valsartan and Candesartan by Telmisartan in Hypertensive Patients With Type 2 DiabetesDiabetes Care, 2005
- Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuriaNephrology Dialysis Transplantation, 2004
- Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ ActivityCirculation, 2004
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential HypertensionHypertension, 2003
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 1998
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 1998